TalkspacevsCerebral
Talkspace
Cerebral
Side-by-side
| # | Product | Active ingredient | Starting price | FDA status | Score | Actions |
|---|---|---|---|---|---|---|
| 1 | Talkspace | — | Best ·— | service | Top ·8.0 | See offer → |
| 2 | Cerebral | — | $85/mo | service | 6.8 | See offer → |
Side-by-side scoring breakdown
How they work
Talkspace is a telehealth platform, not a drug. After a short intake (handled by a bot or matching agent), it pairs you with a licensed therapist (psychologist, LCSW, LMFT, or licensed counselor) based on your stated concerns, location, and preferences. You communicate through a private digital "room" using text, audio, and video messages, with options for scheduled live 30-minute sessions (video, audio, or chat) depending on your plan. A separate Talkspace Psychiatry service connects adults to prescribers who can evaluate you over video and prescribe and manage non-controlled medications (such as antidepressants) sent to your local pharmacy. Care is asynchronous plus synchronous, meaning you can message any time and your therapist typically responds during their working hours, about five days a week.
Cerebral is not a drug or device; it is a telehealth service that connects you to licensed providers online. After a brief intake assessment, you are matched with a therapist for video or phone sessions using evidence-based methods such as cognitive behavioral therapy (CBT), and/or a prescriber who can evaluate you and prescribe non-controlled psychiatric medications (commonly SSRIs and SNRIs) for conditions like depression and anxiety. The platform handles scheduling, secure messaging, and medication coordination, with prescriptions sent to your pharmacy or shipped. The therapeutic benefit comes from the underlying treatments and the provider relationship, not the app itself.
Effectiveness
Talkspace is among the better-studied online therapy platforms, though most of the published evidence comes from observational studies of its own users rather than randomized controlled trials. A study of 10,718 platform users published in BMC Psychiatry (2020) found that roughly 53% of users reduced PHQ-9 depression scores by 5 or more points and about 48% reduced GAD-7 anxiety scores by 5 or more points by their final assessment, with improvement rates the authors described as consistent with face-to-face therapy. A separate naturalistic study of 5,890 clients published in JMIR Formative Research (2022) reported the average client's PHQ-8 depression score improved from 15 to below the clinical cutoff of 10 by week 6, although about 37% of clients had disengaged from therapy by that point. Because these are real-world rather than placebo-controlled outcomes, the results reflect motivated users who stayed engaged and may overstate what a typical or less-engaged user experiences.
There are no clinical trials of Cerebral the company; the relevant evidence is for the treatments it delivers. A 2022 meta-analysis of randomized controlled trials (Giovanetti et al., Telemedicine and e-Health) found video-based psychotherapy essentially equivalent to in-person therapy for depression (Hedges g of about 0.04, i.e., no meaningful difference), with comparable dropout rates. For medication, Cipriani et al.'s 2018 Lancet network meta-analysis of 21 antidepressants found every drug studied was more effective than placebo for acute major depression, with response odds ratios ranging from about 1.37 to 2.13; the broader literature puts the average antidepressant-versus-placebo effect in the modest range (standardized mean difference roughly 0.30). So the modalities Cerebral uses are well supported, while the size of the benefit is moderate and quality depends heavily on your individual provider.
Side effects
Therapy itself has no physical side effects, though briefly feeling worse, emotionally raw, or fatigued after discussing difficult topics is normal. The most common practical drawbacks reported are slow or limited therapist responses on messaging-only plans and occasional therapist mismatches. If you use Talkspace Psychiatry, any prescribed medication carries its own side effects (for example, antidepressants can cause nausea, sleep changes, or sexual dysfunction, and some carry an FDA boxed warning about increased suicidal thoughts in people under 25) that you should discuss with the prescriber. The platform's key limitation is that it is not designed for acute crises and does not provide 24/7 emergency intervention.
Therapy itself carries little physical risk, though some people feel temporary emotional discomfort discussing difficult topics. The main medical risks come from any prescribed medication. SSRIs and SNRIs commonly cause nausea, headache, insomnia or drowsiness, sexual dysfunction, and weight changes. Serious but less common risks include serotonin syndrome, and antidepressants carry an FDA boxed warning for increased suicidal thoughts and behavior in people under 25, especially early in treatment or after dose changes. Never stop an antidepressant abruptly, as this can cause withdrawal symptoms. Report worsening mood, agitation, or suicidal thoughts to your prescriber immediately, and call or text 988 in a crisis.
Cost & value
As of 2026, out-of-pocket Talkspace therapy runs about $69/week ($276/month) for messaging-only, $99/week ($396/month) for messaging plus a weekly live session, and $109/week ($436/month) for messaging, live sessions, and workshops; extra live sessions are about $65 each. Psychiatry is roughly $299 for the initial evaluation, with lower-cost follow-up visits (around $175) and bundle options. The bigger story is insurance: Talkspace is in-network with many major plans (including Aetna, Cigna, Optum, Anthem and Blue Cross Blue Shield, plus Medicare and TRICARE) and through many employers and EAPs, where the company reports an average copay around $10 and that many members pay $0. Always verify your specific coverage first, since with insurance the effective cost can be a fraction of the sticker price. HSA and FSA funds are generally accepted.
As of 2026, out-of-pocket prices are roughly $175 per therapy session (with discounted bundles such as about $795 for three months of regular sessions), around $60 per month for medication management (billed about $180 per quarter, with the medication itself extra), roughly $365 per month for combined medication plus therapy, and about $325 per month for couples therapy; veterans may receive a discount. With in-network insurance (Cerebral lists partners such as Aetna, Blue Cross Blue Shield, Cigna, Optum, and UnitedHealthcare), copays average around $30 per session. Prices change frequently, so confirm current rates, your coverage, and your exact copay before starting, since some users have reported surprise charges.
Who it's for
Talkspace serves U.S. adults seeking therapy for mild-to-moderate concerns such as depression, anxiety, stress, relationship issues, and life transitions, and offers couples therapy and a Teens program for ages 13 to 17 (with parental or guardian consent, with limited legal exceptions). Psychiatry and medication management are limited to adults 18 and older. It is NOT appropriate for psychiatric emergencies, active suicidal or homicidal thoughts, self-harm, or severe, acute conditions such as psychosis or active substance-use crises; in those cases call or text 988 (Suicide and Crisis Lifeline), text START to 741741, or call 911. Talkspace also cannot prescribe controlled substances (for example Adderall, Xanax, Klonopin, Ritalin, Vyvanse, or Valium), so people who specifically need stimulants or benzodiazepines should seek care from a provider who can prescribe them.
Cerebral is designed for US adults 18 and older seeking online therapy or medication management for conditions such as depression, anxiety, insomnia, and bipolar disorder; teen therapy is available in a limited set of states. It is a poor fit for anyone needing controlled substances, including stimulants for ADHD (Adderall, Vyvanse, Ritalin) or benzodiazepines (Xanax), which Cerebral stopped prescribing for most patients in 2022. It is not appropriate for psychiatric emergencies, active suicidal crisis, psychosis, or severe conditions requiring in-person or higher-level care. Anyone in crisis should call or text 988 or go to an emergency room.
Bottom line
Cerebral: Cerebral is a subscription telehealth platform offering online therapy and psychiatric medication management for depression, anxiety, and related conditions across all 50 states. The teletherapy and antidepressants it delivers are evidence-backed treatments. But a history of DOJ and FTC settlements over controlled-substance prescribing, data sharing, and billing means you should watch the subscription terms closely. On balance, Talkspace edges ahead in our scoring, but the right choice depends on your situation.
Conditions these treat
Sources behind our Talkspace and Cerebral reviews
- Message-Based vs Video-Based Psychotherapy for Depression: A Randomized Clinical Trial — JAMA Network Open (2025)
- Message-Based vs Video-Based Psychotherapy for Depression: A Randomized Clinical Trial (PubMed record) — JAMA Network Open / PubMed (2025)
- Comparing Message-Based Psychotherapy to Once-Weekly, Video-Based Psychotherapy for Moderate Depression: Randomized Controlled Trial — Journal of Medical Internet Research (2023)
- Randomized Trial of the Effectiveness of Videoconferencing-Based Versus Message-Based Psychotherapy on Depression — Psychiatric Services (2024)
- A Study of Asynchronous Mobile-Enabled SMS Text Psychotherapy — Telemedicine and e-Health (2017)
- Two-way messaging therapy for depression and anxiety: longitudinal response trajectories — BMC Psychiatry (2020)
- Predictors of Disengagement and Symptom Improvement Among Adults With Depression Enrolled in Talkspace, a Technology-Mediated Psychotherapy Platform: Naturalistic Observational Study — JMIR Formative Research (2022)
- Gender Differences in Trajectories of Depressive Symptoms Among Talkspace Clients: Naturalistic Observational Study — JMIR Formative Research (2025)
- Protocol for a sequential, multiple assignment, randomised trial to test the effectiveness of message-based psychotherapy for depression compared with telepsychotherapy — BMJ Open (2021)
- Messaging Therapy for Depression and Anxiety: A Longitudinal Effectiveness Study (NCT03699488) — ClinicalTrials.gov (U.S. National Library of Medicine) (2018)
- Teletherapy Versus In-Person Psychotherapy for Depression: A Meta-Analysis of Randomized Controlled Trials — Telemedicine and e-Health (2022)
- Best Practices in Videoconferencing-Based Telemental Health (APA/ATA) — American Psychiatric Association & American Telemedicine Association (2018)
- Telepsychiatry Best Practices and Toolkit — American Psychiatric Association (2023)
- Telehealth for the Treatment of Serious Mental Illness and Substance Use Disorders (Evidence-Based Resource Guide) — Substance Abuse and Mental Health Services Administration (SAMHSA) (2021)
- FTC to Ban BetterHelp from Revealing Consumers' Data, Including Sensitive Mental Health Information, to Facebook and Others for Targeted Advertising — U.S. Federal Trade Commission (2023)
- FTC Gives Final Approval to Order Banning BetterHelp from Sharing Sensitive Health Data for Advertising, Requiring It to Pay $7.8 Million — U.S. Federal Trade Commission (2023)
- Psychiatric Treatment Conducted via Telemedicine Versus In-Person Modality in Posttraumatic Stress Disorder, Mood Disorders, and Anxiety Disorders: Systematic Review and Meta-Analysis — JMIR Mental Health (2023)
- Telehealth Company Cerebral Agrees to Pay Over $3.6 Million in Connection with Business Practices that Encouraged the Unauthorized Distribution of Controlled Substances — U.S. Department of Justice (Eastern District of New York) (2024)
- Proposed FTC Order will Prohibit Telehealth Firm Cerebral from Using or Disclosing Sensitive Data for Advertising Purposes, and Require it to Pay $7 Million — Federal Trade Commission (2024)
- Cerebral, Inc. and Kyle Robertson, U.S. v. (Case 222-3067) — Federal Trade Commission, Legal Library (2024)
- Cerebral agrees to $7M settlement with FTC, DOJ over user data sharing, cancellation practices — Fierce Healthcare (2024)
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis — The Lancet (Cipriani A, et al.) (2018)
- Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults — Cochrane Database of Systematic Reviews (Olthuis JV, et al.); PubMed (2016)
- Internet-based cognitive behavioural therapy with therapist support for anxiety in adults: a review of the evidence — Cochrane (2016)
- Depression (NIH Publication, treatment and psychotherapy overview) — National Institute of Mental Health (NIMH) (2024)
- Mental Health Medications (SSRIs, SNRIs, safety and monitoring) — National Institute of Mental Health (NIMH) (2024)
- ZOLOFT (sertraline hydrochloride) Prescribing Information — SSRI label including boxed suicidality warning, serotonin syndrome, sexual dysfunction — DailyMed, U.S. National Library of Medicine (2023)
- EFFEXOR XR (venlafaxine hydrochloride extended-release) Prescribing Information — SNRI label including discontinuation syndrome and suicidality warning — DailyMed, U.S. National Library of Medicine (2023)
- Class Suicidality Labeling Language for Antidepressants (Boxed Warning) — U.S. Food and Drug Administration (Drugs@FDA) (2005)
- Practice Guideline for the Treatment of Patients With Major Depressive Disorder — American Psychiatric Association (2010)
- 988 Suicide & Crisis Lifeline — Substance Abuse and Mental Health Services Administration (SAMHSA) (2024)
Editorial comparison, not medical advice. Discuss options with a qualified clinician. Individual results vary.